Imatinib mesylate (Glivec) is the drug of choice in newly diagnosed patients with chronic myeloid leukemia (CML) 1, 2 and, alone or in combination with chemotherapy, has a significant activity in Philadelphia-positive (Ph þ ) acute lymphoblastic leukemia (ALL). 3, 4 Nonetheless, to date, allogeneic stem cell transplantation (SCT) is the only curative approach to CML. 5 Moreover, responses of Ph þ ALL cases to Imatinib are usually short-lived and these patients are referred, when a donor is available, to SCT.
As the role of Imatinib is gaining ground in the treatment of Ph-positive leukemias, its effects on subsequent allogeneic SCT are still largely unknown. A recent report from Zander et al 6 seems to indicate a higher transplant-related mortality in patients pre-treated with Imatinib for Ph þ acute leukemias, but other studies on Ph þ ALL patients do not confirm these data. [7] [8] [9] We report our experience with Imatinib therapy preceding allogeneic SCT in patients with Ph þ leukemias (ALL and CML).
Between November 2000 and November 2003, 10 patients (four ALL and six CML) were treated with Imatinib before SCT at our Institution. The median age at diagnosis was 40 (range: 30-55) years. The ALL patients received 2-4 courses of chemotherapy (vincristine-adriamycin-prednisone-asparaginase, high dose cytarabineidarubicin, BFM Â 2). Imatinib therapy was started when hematologic recovery after the fourth cycle was documented, or after the second course in the resistant patients. Imatinib daily dose was 400 mg, then rose to 600 if tolerated. The CML patients received either interferonbased therapy (3) or hydroxyurea7cytarabine, then were switched to Imatinib due to intolerance (400 mg) or progression to accelerated-blastic phase (ABP) (600 mg). Six patients started Glivec in remission or chronic phase (CP), four were resistant or in ABP. Four patients were in cytogenetic response, two also in molecular remission.
Imatinib therapy was given for a median of 6 months (range: 2-18) prior to allogeneic SCT. Seven patients (four ALL and three CML) maintained or improved the degree of response, with two cases attaining a major cytogenetic response. Two ALL patients relapsed after 3.5 and 5 months, one CML patient lost cytogenetic response at 12 months and later progressed to AP. Three of 10 patients, one in late CP and two in ABP CML, showed primary resistance to Imatinib. Tolerance to Imatinib was generally good, with 4/10 patients developing grade III or higher toxicity (hematologic toxicity in two cases, hepatic in the other two).
Imatinib therapy was stopped at a median of 1 month (range: 0.5-5) before transplantation.
Allogeneic SCT was performed in cytogenetic remission in three patients, CML-CP in one, ABP in four and relapse of ALL in two cases. Eight patients (80%) underwent transplantation from a matched unrelated donor (MUD), two from an HLA-identical sibling. Stem cell source was peripheral blood in 3/10 cases, bone marrow in 7/10. Median CD34 þ dose was 3.9 Â 10 6 /kg (range: 0.5-6.4). The conditioning regimen included cyclophosphamide (CY) and TBI in eight patients, Busulfan and CY7ATG in two. GVHD prophylaxis consisted of cyclosporine and short-course methotrexate.
Nine of 10 patients engrafted, with a median time to neutrophil (40.5 Â 10 9 /l) and platelet (420 Â 10 9 /l) recovery of 19 (range: 13-29) and 22.5 (range: 17-130) days, respectively. Two patients developed a grade III-IV acute GVHD (skin, liver, bowel) and died 27 and 55 days after SCT, the former still aplastic. Of the eight patients surviving more than 3 months, four (50%) developed chronic GVHD, mild or moderate in three cases and severe in one, with cutaneous and pulmonary involvement. Three patient without cGVHD relapsed after 3.5, 4 and 5.5 months: two patients died while the third attained remission after a second transplant. One CML patient, despite moderate cGVHD, relapsed at the molecular level after 7 months, but returned to BCR/ABL-negative status with Imatinib therapy.
With a median follow-up time of 16 months after SCT (range: 1-26 þ ), 6/10 patients (two ALL and four CML) are alive, in first (3) or second (3) remission. Three patients experienced major infections: two Gram negative pneumonias and one HSV. One patient had CMV reactivation.
We retrospectively analysed nine Ph þ ALL and 30 CML patients who underwent allogeneic SCT, without prior Imatinib therapy, at our Institution in the last 10 years. Despite the small number of cases, which do not allow for reliable statistical analysis, the rates of engraftment and time to recovery (19 days to neutrophils 40.5 Â 10 9 /l and 21 days to platelets 420 Â 10 9 /l) were similar in the patients pre-treated or 'non-pre-treated' with Imatinib. The rate of grade III-IV acute GVHD was slightly higher (10/39, 26%) in the 'non-pre-treated' group. Transplant-related mortality in this cohort of patients was, however, only 8% (3/39), compared to the 20% in the pre-treated patients.
Long-term survival of the patients who received Imatinib before transplantation was satisfactory, considering the advanced phase of disease at transplantation (four CML in accelerated or blast phase and two ALL in relapse) and the large prevalence of transplantation from unrelated donors (8/10).
Our experience confirms the safety of Imatinib therapy preceding allogeneic SCT, as reported by some recent publications. [7] [8] [9] Pre-treatment with Glivec for CML or Ph þ ALL does not seem to affect the transplant procedure in terms of engraftment, incidence of GVHD (both acute and chronic) or infections, even if Imatinib is stopped only few weeks before transplantation. These data are encouraging but deserve confirmation in larger studies. It is very important to define the safety of a therapy which is becoming widely used as first-line treatment of Ph þ CML and ALL. It is therefore likely that, in the future, virtually all patients with Ph-positive leukemias, when referred for allogeneic SCT, will have already received Imatinib.
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